Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic colorectal cancer post chemotherapy.
Systemic Treatment of mCRC Post Standard Chemotherapy
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Maintenance Tucatinib for Advanced HER2+ Breast Cancer
2
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
3
Daily Symptom Shifts Linked to Quality of Life in Metastatic Breast Cancer
4
National PA Week: Mark Honor on the Growth of APPs in Oncology Care
5